Can Medtronic Finally Challenge Intuitive Surgical's Robotic Surgical Systems Dominance?
Medtronic wants a bite of the robotics-assisted surgery market, which could swell to over $63 billion over the next decade.
Can Medtronic Finally Challenge Intuitive Surgical's Robotic Surgical Systems Dominance?
Overview
Medtronic (NYSE: MDT) is one of the world's largest medical technology companies, but it spent years on the outside looking in at the robotic-assisted surgery market. That officially changed in December 2025, when the U.S. Food and Drug Administration (FDA) approved its Hugo robotic-assisted surgery platform for urologic procedures.
A couple of months later, doctors at the Cleveland Clinic successfully used it for the first time. The FDA's approval indicates use for prostatectomy, nephrectomy, and cystectomy procedures. Hospitals perform approximately 230,000 of these annually in the United States.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
- 51% of U.S. adults say the American Dream is out of reach for most people right now: CNBC survey
- A massive 16% market swing just rocked South Korea over 24 hours. The retail ‘ants’ holding the wheel are driving dangerously.
- I’m 60, retired with $3 million. My fiancée, 55, has $1 million but plans to work for the next 10 years. Are we compatible?
